CLINICAL TRIAL SUMMARY

MDACC Study No:2010-0261 (clinicaltrials.gov NCT No: NCT01258998)
Title:Phase II Study of MK-2206 in Patients with Relapsed Lymphoma
Principal Investigator:Yasuhiro Oki
Treatment Agent:MK-2206
Study Status:Closed
Study Description:The goal of this clinical research study is to learn if MK-2206 can help to
control Hodgkin's and non-Hodgkin’s lymphoma. The safety of this drug will also
be studied.

Hide details for General InformationGeneral Information

Disease Group:Hematologic Disorder; Lymphoma
Phase of Study:Phase II
Treatment Agents:MK-2206
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:
Supported By:CTEP
Return Visit:
Home Care:


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Yasuhiro Oki
Dept:Lymphoma/Myeloma
For Clinical Trial Enrollment:713-792-9455
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults